BGPT: Author Review: Kyung-Chul Choi

Explore by Goal

Quick Explanation Copied

Kyung-Chul Choi — science strength snapshot

Evidence in the provided record shows frequent mechanistic preclinical studies (cell lines + mouse xenografts), plus at least one narrative review. Example mechanistic themes include ER/EDC-driven signaling in ovarian cancer cells (e.g., estrogenic gene-expression overlap with estradiol) , cell-cycle/apoptosis modulation by endocrine-active compounds such as methoxychlor/triclosan and reversal by ER antagonism , and preclinical multitarget pharmacology narratives (tangeretin) .

Overall, the provided evidence supports biological plausibility + mechanistic focus, but also flags typical risks: single-model dependence (often BG-1), in vitro-only mechanistic depth in places, limited disclosure/data deposition, and narrative-review selection bias.

Long Explanation

Author Review: Kyung-Chul Choi

Scope constraint: You only provided full extract+numeric data for a small subset of the author’s work. Therefore, the critique below is grounded only in the included DOIs/excerpts and the named numeric values; for the rest of the listed works, I cannot responsibly score rigor or reproducibility without the underlying methods/results.

Visual evidence from the provided raw extracts

These plots use the explicit numeric values embedded in your extracts (no placeholder data, no simulation).

The excerpt states: “RES … 100 µM reduces by 64% relative to vehicle” in an MTT assay context .

The excerpt reports groupwise mean CPK values at admission and postoperative days; here we display POD1 and POD7 means for each technique .

Scientific content assessment (what is known vs inferred)

Mechanistic intent is frequent: the excerpts emphasize pathway-level changes (ER dependency; cell cycle markers; apoptosis markers; transcription factors; EMT/CSC themes). Example: BPA and estradiol produce overlapping ER-responsive gene expression in ER+ BG-1 cells .
ER-dependence is sometimes experimentally tested: MXC/triclosan proliferative gene/protein shifts are reported as reversed by the ER antagonist ICI 182,780 in ER+ BG-1 cells .
Translation-aware critique is present at least in some contexts: the tangeretin paper explicitly frames limitations such as narrative-review selection bias, reliance on preclinical models, and PK/active-metabolite complexity .

Rigor & bias analysis (skeptical checklist)

1) Model dependence & generalizability

Single-cell-line risk: the ER-centric excerpts rely heavily on the BG-1 ovarian cancer model. Even when mechanistic markers are altered, phenotypes and pathway wiring can differ across tumor genotypes and microenvironments; the excerpted limitations explicitly highlight in vitro model constraints for the microarray study .
Cross-compound concentrations: endocrine-active compounds are frequently tested at concentrations that may be far from typical human exposures. The microarray and MXC/TCS excerpts include chemical concentration ranges and discuss biological context as a risk of over-interpreting; you should treat “estrogenic effect” claims as conditional on dose and cellular context ; .

2) Statistical & reproducibility signals

RNA pooling can reduce biological-replicate interpretability: the microarray study (BPA vs E2) pools RNA for microarray (n=4 treated groups pooled, n=3 pooled controls in excerpt), which compresses variance estimates .
Semi-quantitative RT-PCR rather than qPCR appears in the resveratrol BG-1 excerpt, and replicate counts are not always explicit; this can weaken reproducibility relative to quantitative methods .
Data sharing / deposition is not demonstrated in the excerpts: the provided extracts for these studies state “not provided” or “no data availability” for deposition, which makes independent re-analysis harder (a reproducibility concern) ; .

3) Evidence strength mapping (from the provided material)

Evidence Type	Example from provided record	Reliability (based on excerpt)
Pathway-linked transcriptional overlap	E2 vs BPA shared ER-responsive gene set in BG-1	Moderate (pooling + in vitro constraints)
Pharmacology with mechanistic dependence tests	MXC/TCS effects reversed by ER antagonist (ICI 182,780)	Moderate (single model; in vitro focus)
Preclinical translational synthesis	Tangeretin narrative review of mechanisms + PK challenges	Weak (selection bias risk; not primary data)
Clinical biomarker comparison	CPK/CRP + MRI CSA to compare surgical invasiveness	Moderate (small/short-term; non-randomized risk if not stated)

The clinical vignette excerpt includes limits: small sample size, short-term outcomes, lack of CPK isoenzyme specificity, and single-center design .

Synthesis: what the provided evidence most supports

ER-linked mechanistic claims are supported in multiple provided excerpts by the logic of “compound → ER-responsive gene/protein shifts → antagonist reversal.” For BPA vs estradiol, the excerpt shows overlapping ER-responsive genes in BG-1 . For MXC/TCS, antagonist reversal supports ER dependence in the excerpt .
Preclinical “multi-target” narratives exist (tangeretin), but are lower-evidence strength in the strict epistemic sense because the excerpt is explicitly narrative and non-systematic .
PK and exposure complexity are at least acknowledged in the tangeretin record via explicit rat oral PK values (Tmax, Cmax) and a stated bioavailability context .

What would most disprove the strongest claims (falsification targets)

For ER-dependent gene/protein claims in BG-1: demonstrate that antagonist reversal fails or that ER knockdown/alternative ER signaling perturbations do not abolish the effect (the excerpt already positions ER dependence via ICI in MXC/TCS) .
For “compound drives pathway/phenotype” claims: show that measured marker changes (cyclin D1/p21/Bax) do not causally mediate viability/apoptosis phenotypes, e.g., by epistasis experiments (not provided in the excerpts).
For narrative multivariable “clinical translation” enthusiasm: show discordant PK exposures, metabolite inactivity, or lack of effect in better-controlled models. The tangeretin excerpt explicitly anticipates translation uncertainty due to PK/bioavailability/metabolites .

Citation metrics & publication-shape caution

Bibliometrics provided: you supplied h-index/citation counts and an approximate OpenAlex profile match. These numbers correlate with impact, but do not by themselves validate mechanistic correctness; high citation counts can reflect review/utility and citation behavior, not causal truth.
Important epistemic caution: the provided OpenAlex snippet appears to be ambiguous across similarly named authors. For example, OpenAlex “matches” list multiple Kyung-Chul/Kyung-Chul-like identities with different ORCIDs and metrics; therefore, any precise interpretation of bibliometrics must be treated as uncertain unless the ORCID matches the same person. (I’m not adding extra claims here because no authoritative DOI-backed linkage was provided for the OpenAlex entries.)

Feedback:

Updated: April 16, 2026